
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc is well-positioned for growth with a focus on developing innovative therapies for significant unmet medical needs in oncology and COVID-19 treatment. The company’s current valuation is deemed attractive, with updated net present value (NPV) analyses indicating considerable upside potential for its stock price. Achieving key clinical milestones and data is anticipated to serve as strong catalysts, strengthening the overall positive outlook for the company's financial future.
Bears say
Atossa Therapeutics Inc. reported a net loss of $8.7 million, equating to an earnings per share (EPS) of $(0.07), which matched previous estimates but raises concerns over consistent financial performance, given prior losses of $8.4 million at the same EPS level. The company faces numerous significant risks that could impede its financial recovery and growth, including potential failures in clinical trials, regulatory approval process hurdles, and challenges in commercialization and market competition. Additionally, the reliance on successful product development amidst fluctuating investor sentiment and macroeconomic conditions further compounds the overall negative outlook on the stock.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares